Company profile
SIGA TECHNOLOGIES INC
NASDAQ:SIGABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TECOVIRIMAT | approved | — | 5 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02474589 | phase3 | completed | 2015-06-19 | 2016-08-24 | SIGA Technologies | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat |
| NCT04485039 | phase4 | completed | 2022-06-08 | 2022-12-15 | SIGA Technologies | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders |
| NCT00728689 | phase1 | completed | 2008-08-01 | 2008-10-01 | SIGA Technologies | Phase I Trial of an Investigational Small Pox Medication |
| NCT00431951 | phase1 | completed | 2007-02-01 | 2008-02-01 | SIGA Technologies | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers |
| NCT04392739 | phase4 | completed | 2019-07-19 | 2019-12-05 | SIGA Technologies | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 208627 | NDA | SIGA TECHNOLOGIES INC | ||||
Loading… | ||||||
| NDA 214518 | NDA | SIGA TECHNOLOGIES INC | ||||
Loading… | ||||||